Up next

Autoplay

FDA Approves of Biosimilar to Infliximab – IBD in the News

1 Views • 08/19/25
Share
Side Effects
Side Effects
Subscribers
0

The FDA recently approved of a biosimilar (CT-P13) to infliximab, which is used for treating IBD patients, as well as patients suffering from rheumatoid arthritis ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The new drug would be the first biosimilar monoclonal antibody approved in the United States.
Dr. Edward Loftus, M.D., discusses some of the issues surrounding this medication, and its potential benefits and drawbacks.

Learn More:

http://ibdblog.mayoclinic.org

Join our interactive SOCIAL MEDIA community:

► YouTube: http://YouTube.com/MayoClinic
► Facebook: http://Facebook.com/MayoClinic
► Twitter: http://Twitter.com/MayoClinic
► Google+: http://bit.ly/MayoClinicGoogle
► Pinterest: http://Pinterest.com/MayoClinic
► Flickr: http://Flickr.com/MayoClinic
► Mayo Clinic Connect: http://MayoClinic.org/connect

Follow our BLOGS:

► Patient Stories: http://Sharing.MayoClinic.org
► News Network: http://NewsNetwork.MayoClinic.org
► Research and Science: http://AdvancingTheScience.Mayo.edu
► Mayo Clinic Radio: http://Radio.MayoClinic.org
► Mayo Clinic Podcasts: http://Podcasts.MayoClinic.org
► Mayo Clinic's WEB SITE: http://MayoClinic.org

Show more
0 Comments sort Sort By

Up next

Autoplay